Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents.
The PFA-100 (Dade) is a new functional whole blood analyzer, the accuracy and reliability of which have been evaluated in von Willebrand disease and during acetyl salicylate acid therapy. This new test has the advantages of rapidity and simplicity. It may be useful to monitor new antiplatelet agents, such as GPIIb/IIIa receptor antagonists. The objective of this study was to assess the PFA-100 in comparison with aggregometry and with the percentage of blockaded receptors GPIIb/IIIa during and after c7E3 Fab infusion in fifteen patients undergoing PTCA. Our results showed a change of closure time values from normal to abnormal within a small margin of flow cytometric values (60-75% of blockaded receptors), and moreover a variable platelet response to long-term low dose aspirin treatment in agreement with aggregometry. No influence with heparin was observed. In conclusion, this study shows that PFA-100 may be helpful in the decision making for additional antiaggregant therapy before PTCA or in monitoring long-term GPIIb/IIIa receptor antagonist treatment.
Hézard
N
N
Laboratoire Central d'Hématologie, CHU Robert Debré, Reims, France.
Metz
D
D
Nazeyrollas
P
P
Droulle
C
C
Elaerts
J
J
Potron
G
G
Nguyen
P
P
D000077284:Abciximab; D000244:Adenosine Diphosphate / Q000494:pharmacology; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001772:Blood Cell Count; D003094:Collagen / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D004867:Equipment Design; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008838:Microcomputers; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D010979:Platelet Function Tests / Q000295:instrumentation*; D011655:Pulmonary Embolism / Q000097:blood
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D006454:Hemoglobins; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000244:Adenosine Diphosphate; D006493:Heparin; D003094:Collagen; D000077284:Abciximab; D004837:Epinephrine